AFP
1 EU-approved indication of 1 drug needs a AFP result, in 1 tumour type, most of them in hepatocellular carcinoma.
Approved indications1
| Drug | Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|---|
| Hepatocellular carcinoma1 | ||||
Cyramza | Serum AFP ≥ 400 ng/ml | Monotherapy | 2L advanced | After sorafenib |
AFP by tumour
Label wording1
The sentence from section 4.1 of the SmPC that each indication above comes from.
- Ramucirumab (Cyramza)
Cyramza monotherapy is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have a serum alpha fetoprotein (AFP) of ≥ 400 ng/ml and who have been previously treated with sorafenib.